US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
Mike Dolph, 1 Gabriel Tremblay, 1 Hoyee Leong 2 1Health Economics Department, Purple Squirrel Economics, New York, NY, 10010, USA; 2Health Economics and Outcomes Research, Global Medical and Scientific Affairs, Karyopharm Therapeutics, Newton, MA, 02459, USACorrespondence: Hoyee Leong Email hleong@k...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2021-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Mike Dolph, 1 Gabriel Tremblay, 1 Hoyee Leong 2 1Health Economics Department, Purple Squirrel Economics, New York, NY, 10010, USA; 2Health Economics and Outcomes Research, Global Medical and Scientific Affairs, Karyopharm Therapeutics, Newton, MA, 02459, USACorrespondence: Hoyee Leong Email hleong@karyopharm.comPurpose: To estimate the budget impact of selinexor, bortezomib, and dexamethasone (XVd) in patients with previously treated multiple myeloma (MM) from the perspective of a private third-party payer and Medicare in the US.Methods: The introduction of XVd as an option for patients with previously treated MM compared to no introduction of XVd was considered from a private third-party US payer (with 1,000,000 members) and a Medicare perspective in one-year increments for 3 years. Total annual treatment costs were calculated as the sum of drug costs, costs of treating serious treatment emergent adverse events (grade ≥ 3), ongoing best supportive care costs, and mortality costs.Results: The absolute budget impact (Millions, USD) of including XVd from a private third-party payer plan perspective was |
|---|---|
| Item Description: | 1178-6981 |